Breaking News Instant updates and real-time market news.

OAS

Oasis Petroleum

$12.50

0.21 (1.71%)

, OMP

Oasis Midstream Partners

$18.12

0.53 (3.01%)

04:55
06/20/18
06/20
04:55
06/20/18
04:55

JPMorgan to hold a conference

3rd Annual Energy Equity Conference will be held in New York on June 18-20.

OAS

Oasis Petroleum

$12.50

0.21 (1.71%)

OMP

Oasis Midstream Partners

$18.12

0.53 (3.01%)

SRCE

1st Source

$56.34

0.74 (1.33%)

LGCY

Legacy Reserves

$6.72

0.22 (3.38%)

EVA

Enviva

$28.75

-0.5 (-1.71%)

CRC

California Resources

$37.11

0.62 (1.70%)

INSM

Insmed

$27.48

0.87 (3.27%)

  • 20

    Jun

  • 28

    Sep

OAS Oasis Petroleum
$12.50

0.21 (1.71%)

05/23/18
MSCO
05/23/18
UPGRADE
MSCO
Overweight
Oasis Petroleum upgraded to Overweight from Equal Weight at Morgan Stanley
05/23/18
MSCO
05/23/18
UPGRADE
MSCO
Overweight
Whiting Petroleum, Oasis Petroleum upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Drew Venker upgraded both Whiting Petroleum (WLL) and Oasis Petroleum (OAS), each to Overweight from Equal Weight, citing stronger oil prices, improving capital discipline, and positive momentum in the Bakken play. He raised his price target on Whiting to $71 from $43 and increased his price target for Oasis to $19 from $11. Venker also increased his price targets on several other mid-cap E&Ps, including Antero Resources (AR), Continental Resources (CLR), Diamondback Energy (FANG), Energen (EGN), EQT (EQT), Gulfport (GROR), Parsley (PE), Range Resources (RRC) and Southwestern Energy (SWN).
06/11/18
JEFF
06/11/18
NO CHANGE
JEFF
Jefferies upgrades Cimarex to Buy, downgrades Oasis to Hold
Jefferies analyst Mark Lear upgraded Cimarex Energy (XEC) to Buy from Hold and raised his price target for the shares to $107 from $98. The analyst also downgraded Oasis Petroleum (OAS) to Hold from Buy with an unchanged price target of $14. Infrastructure constraints and wider regional basis have raised growth concerns across the Permian and driven stocks to "irrational valuations," Lear tells investors in a research note. Jefferies also raised its per-barrel Brent price forecast to $77 from $64 in 2018; to $75 from $60 in 2019; and to $70 from $65 in 2020. He notes shares of Cimarex now trade at "more than half a turn discount" to the group on consensus 2018 and 2020 EBITDA. Lear believes Cimarex's recent moves to address gas flow assurance in tandem with strategic partnerships in the Permian "provide some level of relative safety on the company's ability to maintain capital guidance." The analyst cites valuation for his downgrade of Cimarex following the stock's outperformance year-to-date.
06/11/18
JEFF
06/11/18
DOWNGRADE
Target $14
JEFF
Hold
Oasis Petroleum downgraded to Hold from Buy at Jefferies
Jefferies analyst Mark Lear downgraded Oasis Petroleum to Hold with an unchanged price target of $14.
OMP Oasis Midstream Partners
$18.12

0.53 (3.01%)

10/24/17
JRCO
10/24/17
INITIATION
JRCO
Buy
Oasis Midstream Partners initiated with a Buy at Johnson Rice
Johnson Rice analyst Georg Venturatos initiated Oasis Midstream Partners (OMP) with a Buy saying it offers attractive, visible growth, supported by a sizeable backlog of drop-down opportunities and organic growth through Oasis Petroleum (OAS) activity.
10/16/17
MSCO
10/16/17
INITIATION
Target $22
MSCO
Overweight
Oasis Midstream Partners initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Tom Abrams initiated Oasis Midstream Partners with an Overweight rating and $22 price target, saying he sees the units as attractively valued given his expectation for 25% DCF/unit growth through 2020.
10/16/17
10/16/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Hold at Aegis. 2. Best Inc. (BSTI) was initiated with a Buy at Deutsche Bank, Stifel, and Goldman Sachs, an Outperform at Credit Suisse, as well as an Overweight at KeyBanc. 3. Oasis Midstream Partners (OMP) was initiated with an Overweight at Morgan Stanley and JPMorgan, an Outperform at RBC Capital, a Buy at Citi and Goldman Sachs, as well as a Market Perform at Wells Fargo. 4. Zai Lab (ZLAB) was initiated with a Buy at Citi and a Neutral at JPMorgan. 5. Despegar.com (DESP) was initiated with a Neutral at UBS, an Overweight at KeyBanc, an Equal Weight at Morgan Stanley, and a Neutral at UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/18
FBCO
01/04/18
INITIATION
FBCO
Neutral
Oasis Midstream Partners initiated with a Neutral at Credit Suisse
Credit Suisse analyst Kristina Kazarlan initiated Oasis Midstream Partners with a Neutral rating and a price target of $19. Kazarlan said this small-cap MLP with fewer immediate catalysts is fairly valued.
SRCE 1st Source
$56.34

0.74 (1.33%)

10/23/17
DADA
10/23/17
NO CHANGE
Target $53
DADA
Neutral
1st Source price target raised to $58 from $48 at DA Davidson
DA Davidson analyst Kevin Reevey raised his price target on 1st Source to $53 following Q3 results that showed 2.9% growth in spread income and a 6% growth in fee income. Reevey notes that strong loan originations were only slightly offset by paydowns, and net interest margins remained stable relative to prior quarter. The analyst maintains a Neutral rating to reflect the recent run-up in bank valuations.
LGCY Legacy Reserves
$6.72

0.22 (3.38%)

05/14/18
UBSW
05/14/18
UPGRADE
UBSW
Neutral
Legacy Reserves upgraded to Neutral from Sell at UBS
EVA Enviva
$28.75

-0.5 (-1.71%)

05/14/18
RBCM
05/14/18
NO CHANGE
Target $33
RBCM
Outperform
Enviva price target lowered to $33 from $37 at RBC Capital
RBC Capital analyst Elvira Scotto lowered her price target on Enviva to $33 after its Q1 earnings miss, saying the results were "noisy" because of the costs associated with the Chesapeake terminal fire. The analyst notes however that Chesapeake expects to recover those costs and achieve its FY18 guidance. Scotto also keeps her Outperform rating on Enviva based on its status of a "leading supplier of utility-grade wood pellets" and its "highly visible top-tier distribution growth" over the coming years.
09/22/17
09/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Overweight from Equal Weight at Barclays with analyst Brandon Oglenski saying the company appears to have all the attributes of a "value compounding opportunity" for equity investors. 2. Mindbody (MB) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brent Bracelin saying elevated churn risk from the company's model transition to higher-value subscribers is now discounted into the valuation. 3. Enviva (EVA) upgraded to Buy from Neutral at Citi with analyst Ryan Levine saying he likes the risk/reward at current levels and believes Enviva is well positioned in the next 12-18 months. 4. PSEG (PEG) upgraded to Overweight from Equal Weight at Barclays with analyst Gregg Orrill saying the company could be the industry's largest beneficiary of potential near-term policy initiatives. 5. AstraZeneca (AZN) upgraded to Outperform from Market Perform at Bernstein with analyst Tim Anderson saying that the outlook of its current products has improved, leaving it well-positioned to grow even if its pipeline does not yield any new drugs through 2025. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/17
SBSH
09/22/17
UPGRADE
Target $34
SBSH
Buy
Enviva upgraded to Buy from Neutral at Citi
Citi analyst Ryan Levine upgraded Enviva Partners to Buy and raised his price target for the shares to $34 from $28. The analyst likes the risk/reward at current levels and believes Enviva is well positioned in the next 12-18 months. Levine sees "material" upside potential if the company continues to sign Japanese wood pellet contracts.
CRC California Resources
$37.11

0.62 (1.70%)

04/26/18
SOCG
04/26/18
DOWNGRADE
SOCG
Hold
California Resources downgraded to Hold from Buy at Societe Generale
05/17/18
IMPC
05/17/18
NO CHANGE
Target $41
IMPC
Outperform
California Resources price target raised to $41 from $35 at Imperial Capital
Imperial Capital analyst Jason Wangler raised his price target for California Resources to $41 saying oil price strength continues to indicate higher cash flows for the company. Increased cash flows from favorable production and higher oil prices provide optionality for the company as it looks to add production and reduce debt, Wangler tells investors in a research note. He keeps an Outperform rating on the shares.
02/12/18
IMPC
02/12/18
UPGRADE
Target $26
IMPC
Outperform
California Resources upgraded to Outperform from In-Line at Imperial Capital
Imperial Capital analyst Jason Wangler upgraded California Resources to Outperform with an unchanged price target of $26 following the company's announcement of a new midstream joint venture and equity investment. The analyst views the developments as further evidence of the value in the company's asset base.
02/09/18
SOCG
02/09/18
UPGRADE
SOCG
Buy
California Resources upgraded to Buy from Hold at Societe Generale
INSM Insmed
$27.48

0.87 (3.27%)

04/23/18
04/23/18
UPGRADE
Target $33

Outperform
Insmed upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Martin Auster upgraded Insmed to Outperform from Neutral and raised his price target on the shares to $33 from $27. While he continues to believe payer control of access to NTM MAC treatment carries some uncertainty and commercial risk for ALIS, Auster also sees expression of significant unmet need and high intent to treat from clinicians as a meaningful offset. Longer-term, the analyst points to ALIS first-to-market/strong competitive position and highly durable IP as factors supporting a longer-term M&A thesis, though he believes initial de-risking of the market opportunity may be needed first.
04/23/18
FBCO
04/23/18
UPGRADE
FBCO
Outperform
Insmed upgraded to Outperform from Neutral at Credit Suisse
03/21/18
MSCO
03/21/18
INITIATION
Target $39
MSCO
Overweight
Insmed initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison started Insmed with an Overweight rating and $39 price target, as he believes data from its treatment of nontuberculous mycobacteria is strong enough that he estimates $400M-500M of peak U.S. sales. However, while Harrison thinks the market sees the value in the refractory population, it appears to be missing the key upside drivers of expansion into maintenance therapy, geographic expansion to Japan and potentially even frontline treatment, he tells investors.
03/14/18
LEER
03/14/18
NO CHANGE
Target $39
LEER
Outperform
Concern about AdCom, off-cycle launch priced into Insmed, says Leerink
Leerink analyst Joseph Schwartz noted that Insmed's shares have pulled back ahead of NDA submission this month for ALIS. The analyst believes the stock's weakness has been driven by investor angst over the anticipated advisory committee AdCom panel this summer and headwinds from an "off-cycle" launch for Medicare. Schwartz expects the company to fare well and believes investor's fears have provided an attractive buying opportunity. He reiterates an Outperform rating and $39 price target on the shares.

TODAY'S FREE FLY STORIES

SKX

Skechers

$26.10

-0.59 (-2.21%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
Skechers sees Q4 EPS 20c-25c, consensus 18c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

EGP

EastGroup Properties

$93.63

0.13 (0.14%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
EastGroup Properties reports Q3 FFO $1.17, consensus $1.14 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 07

    Nov

EXPO

Exponent

$47.38

-1.12 (-2.31%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
Exponent sees FY18 revenue growth in high-single digits »

Exponent CFO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TEAM

Atlassian

$82.36

-1.27 (-1.52%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
Atlassian sees FY19 EPS 78c, consensus 77c »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SKX

Skechers

$26.13

-0.56 (-2.10%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Earnings
Skechers reports Q3 EPS 58c, consensus 51c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CRBP

Corbus Pharmaceuticals

$7.83

0.29 (3.85%)

16:09
10/18/18
10/18
16:09
10/18/18
16:09
Hot Stocks
Corbus Pharmaceuticals presents new data on lenabasum at NACFC »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTT

CatchMark Timber

$9.63

-0.21 (-2.13%)

16:08
10/18/18
10/18
16:08
10/18/18
16:08
Hot Stocks
CatchMark Timber reports 'negligible damage' from recent Hurricanes »

CatchMark Timber Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

AKTS

Akoustis

$5.02

-0.735 (-12.78%)

16:08
10/18/18
10/18
16:08
10/18/18
16:08
Syndicate
Akoustis Spot Secondary price range $4.00-$4.25 »

Oppenheimer is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

TEAM

Atlassian

$82.18

-1.45 (-1.73%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Earnings
Atlassian sees Q2 EPS 21c, consensus 20c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ISRG

Intuitive Surgical

$526.20

-16.65 (-3.07%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Earnings
Intuitive Surgical reports Q3 EPS $2.83, consensus $2.66 »

Reports Q3 revenue $921M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

AXP

American Express

$102.49

-1.9 (-1.82%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Earnings
American Express raises FY18 EPS view to $7.30-$7.40 from $6.90-$7.30 »

Consensus $7.27. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 05

    Nov

WDFC

WD-40

$157.22

-0.45 (-0.29%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Earnings
WD-40 reports Q4 EPS $1.54, one estimate 99c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 29

    Nov

  • 30

    Nov

IMMU

Immunomedics

$22.74

0.38 (1.70%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Initiation
Immunomedics initiated  »

Immunomedics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 18

    Jan

FOXA

21st Century Fox

$45.73

-0.09 (-0.20%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Periodicals
Fox Business withdraws as sponsor of Saudi conference, The Wrap reports »

Fox Business Network has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

FFIN

First Financial

$56.98

-1.14 (-1.96%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Earnings
First Financial reports Q3 adjusted EPS 52c, consensus 57c »

The net interest margin,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPO

Exponent

$47.38

-1.12 (-2.31%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Earnings
Exponent reports Q3 EPS 32c, consensus 29c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SOLO

ElectraMeccanica

$2.58

-0.125 (-4.63%)

16:07
10/18/18
10/18
16:07
10/18/18
16:07
Syndicate
Breaking Syndicate news story on ElectraMeccanica »

ElectraMeccanica files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 29

    Nov

TEAM

Atlassian

$82.38

-1.25 (-1.49%)

16:06
10/18/18
10/18
16:06
10/18/18
16:06
Earnings
Atlassian reports Q1 EPS 20c, consensus 19c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

PBCT

People's United

$16.16

-0.19 (-1.16%)

16:06
10/18/18
10/18
16:06
10/18/18
16:06
Earnings
People's United reports Q3 EPS 33c, consensus 33c »

Reports Q3 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

AXP

American Express

$102.57

-1.82 (-1.74%)

16:06
10/18/18
10/18
16:06
10/18/18
16:06
Earnings
American Express reports Q3 EPS $1.88, consensus $1.76 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 05

    Nov

CP

Canadian Pacific

$199.70

-6.25 (-3.03%)

16:05
10/18/18
10/18
16:05
10/18/18
16:05
Earnings
Canadian Pacific expects adjusted diluted EPS for 2018 to grow in excess of 20% »

Due to a record-setting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

FVCB

FVCBankcorp

$18.50

-0.27 (-1.44%)

16:04
10/18/18
10/18
16:04
10/18/18
16:04
Earnings
FVCBankcorp reports Q3 EPS 27c, consensus 28c »

Reports Q3 NII $9.9M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVU

Supervalu

$32.49

0.02 (0.06%)

, UNFI

United Natural Foods

$26.97

0.23 (0.86%)

16:03
10/18/18
10/18
16:03
10/18/18
16:03
Hot Stocks
Supervalu stockholders approve merger with United Natural Foods »

Supervalu (SVU) announced…

SVU

Supervalu

$32.49

0.02 (0.06%)

UNFI

United Natural Foods

$26.97

0.23 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 28

    Oct

CP

Canadian Pacific

$199.44

-6.51 (-3.16%)

16:03
10/18/18
10/18
16:03
10/18/18
16:03
Hot Stocks
Canadian Pacific CEO says set up well for remainder of year and beyond »

"This quarter really…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

AKTS

Akoustis

$5.05

-0.7 (-12.17%)

16:03
10/18/18
10/18
16:03
10/18/18
16:03
Syndicate
Akoustis files to sell common stock and $10M in convertible senior notes »

Akoustis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.